Investments (Uk) Ltd Soft B... Net Worth

The estimated Net Worth of Investments (Uk) Ltd Soft B... is at least $1.1 milliárd dollars as of 4 June 2019. Investments B owns over 2,424,242 units of Myovant Sciences Ltd stock worth over $1,099,855,861 and over the last 7 years Investments sold MYOV stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Investments B MYOV stock SEC Form 4 insiders trading

Investments has made over 2 trades of the Myovant Sciences Ltd stock since 2018, according to the Form 4 filled with the SEC. Most recently Investments bought 2,424,242 units of MYOV stock worth $19,999,997 on 4 June 2019.

The largest trade Investments's ever made was buying 2,424,242 units of Myovant Sciences Ltd stock on 4 June 2019 worth over $19,999,997. On average, Investments trades about 589,043 units every 71 days since 2017. As of 4 June 2019 Investments still owns at least 40,765,599 units of Myovant Sciences Ltd stock.

You can see the complete history of Investments B stock trades at the bottom of the page.

Insiders trading at Myovant Sciences Ltd

Over the last 8 years, insiders at Myovant Sciences Ltd have traded over $5,780,890 worth of Myovant Sciences Ltd stock and bought 96,585,963 units worth $2,001,605,371 . The most active insiders traders include Sciences Ltd. Roivant, Global Investors Lp Viking ... és Andrew Lo. On average, Myovant Sciences Ltd executives and independent directors trade stock every 15 days with the average trade being worth of $25,106,967. The most recent stock trade was executed by Chemical Co., Ltd.Sumitomo ... on 10 March 2023, trading 51,599,200 units of MYOV stock currently worth $1,393,178,400.

What does Myovant Sciences Ltd do?

Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Myovant Sciences has one FDA-approved medicine, ORGOVYX™ (relugolix), for adult patients with advanced prostate cancer. Its lead product candidate, relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg), is under regulatory review in Europe and the U.S. for women with uterine fibroids and is under development for women with endometriosis. Myovant Sciences is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is its majority shareholder.

Complete history of Investments B stock trades at Arbutus Biopharma Corp és Myovant Sciences Ltd

Myovant Sciences Ltd executives and stock owners

Myovant Sciences Ltd executives and other stock owners filed with the SEC include:

• Lynn Seely,
  Principal Executive Officer, Director
• Matthew Lang,
  General Counsel, Corporate Secretary and Chief Legal and Administrative Officer and Corporate Secretary of Myovant Sciences, Inc.
• Frank Karbe,
  Principal Financial and Accounting Officer, President and Chief Financial Officer of Myovant Sciences, Inc.
• Juan Camilo Arjona Ferreira,
  Chief Commercial Officer - Myovant Sciences, Inc
• David C. Marek,
  CEO & Director
• Matthew Lang J.D.,
  Gen. Counsel & Corp. Sec.
• Kathleen Sebelius,
  Lead Independent Director
• Myrtle Potter,
  Chairman of the Board
• Mark Guinan,
  Independent Director
• Terrie Curran,
  Independent Director
• Adele Gulfo,
  Director, Interim Chief Commercial Officer
• Hiroshi Nomura,
  Director
• Dr. Andria Langenberg M.D.,
  Head of Drug Safety & Pharmacovigilance
• Dr. Teresa Perney Ph.D.,
  Sr. VP of Regulatory Affairs & Quality Assurance
• Dr. Juan Camilo Arjona Ferreira M.D.,
  Chief Medical Officer
• Bryan Selby,
  Sr. VP of Product Devel.
• Julie Tran MBA, MSHR,
  Sr. VP of HR
• Albert Liao,
  Director of Corp. Communications
• Ryan Crowe,
  VP of Investor Relations
• Uneek Mehra,
  Chief Financial & Bus. Officer
• Kim Sablich,
  Chief Commercial Officer
• Uneek Mehra,
  Principal Financial Officer
• David C Marek,
  Principal Executive Officer
• Wayne S De Veydt,
  Director
• Mark Altmeyer,
  Director
• Pharmaceuticals Internation...,
  10% owner
• Global Investors Lp Viking ...,
  
• Holdings Ltd.Dexcel Pharma ...,
  
• Global Performance Llc Viki...,
  
• Investments (Uk) Ltd Soft B...,
  
• Sciences Ltd. Roivant,
  10% owner
• Patrick Machado,
  
• Associates Gp Llcqvt Fund V...,
  
• Global Performance Llc Viki...,
  
• Pharmaceuticals Internation...,
  
• Frank Torti,
  Director
• Chemical Co., Ltd.Sumitomo ...,
  
• Lauren Merendino,
  Chief Commercial Officer
• Nancy Valente,
  Director